首页 » 文章 » 文章详细信息
International Journal of Endocrinology Volume 2019 ,2019-07-18
Aliskiren, Fosinopril, and Their Outcome on Renin-Angiotensin-Aldosterone System (RAAS) in Rats with Thyroid Dysfunction
Research Article
Susan A. S. Farhadi 1 Kawa F. Dizaye 1
Show affiliations
DOI:10.1155/2019/5960563
Received 2019-03-02, accepted for publication 2019-06-19, Published 2019-06-19
PDF
摘要

Background and Objectives. Thyroid hormones have an important role in the growth and development of various tissues including the kidney, which is the major site of renin release and the consequent angiotensin and aldosterone formation. Therefore any derangement in thyroid function can result in abnormal functioning in the renin-angiotensin-aldosterone system. The current study was undertaken to find the impact of using a direct renin inhibitor (Aliskiren) and an angiotensin-converting enzyme inhibitor (Fosinopril) on the components of the renin-angiotensin-aldosterone system (RAAS) in rats with thyroid dysfunctions. Method. Forty-two male albino rats were divided into three subgroups. First group (6 rats) served as control. Second group (18 rats) served as hyperthyroid group (6 rats positive control, 6 rats given Aliskiren, and 6 rats given Fosinopril). Third group (18 rats) served as hypothyroid group (6 rats positive control, 6 rats given Aliskiren, and 6 rats given Fosinopril). Induction of hyperthyroidism and hypothyroidism was done through daily oral administration of L-Thyroxine and Propylthiouracil, respectively. On day 40 of the study, the rats were sacrificed and blood was collected for estimation of renin, angiotensin I, angiotensin II, aldosterone, TSH, T3, and T4. The collected blood samples were also used for estimation of levels blood urea, serum creatinine, liver enzymes, and serum electrolytes. Blood pressure and urine collection were done on days 1 and 40. The collected urine was used for estimation of urine flow, sodium excretion, and potassium excretion rates. Results. In hypothyroid induced rats, serum renin level dropped as expected, while the use of Aliskiren and Fosinopril on these hypothyroid rats raised renin level due to the feedback mechanism. Both angiotensin I and II were significantly (P <0.05) lower than normal levels in the hypothyroid rats, unlike the level of aldosterone, which was higher than normal level. There was nonsignificant lowering in BP (systolic, diastolic, and mean BP) in the hypothyroid rats. Treatment of these rats with Aliskiren and Fosinopril did not lower the blood pressure more than normal when compared to the hypothyroid group. The hypothyroid rats also showed a decrease in level of serum creatinine. In hyperthyroid rats, there was a rise in levels of serum renin, angiotensin II, and aldosterone; nevertheless, the increase in angiotensin I level was significant. The use of Aliskiren and Fosinopril increased the level of renin nonsignificantly (decreased angiotensin I significantly). Hyperthyroid rats showed a significant increase in systolic, diastolic, and mean blood pressure. Both Aliskiren and Fosinopril increased urine flow, Na+   excretion, and K+ excretion rates. Aliskiren was better at reducing the high blood pressure. Conclusion. Aliskiren and Fosinopril in hyperthyroid rats decreased serum angiotensin I, angiotensin II, and aldosterone. Blockade of renin and inhibition of angiotensin-converting enzyme both resulted in a rebound increase in level of renin in hypothyroid rats. Aliskiren is better at controlling blood pressure in hyperthyroid rats. Urine flow, sodium excretion, and potassium excretion rates were improved by the use of Aliskiren and Fosinopril in hyperthyroid rats.

授权许可

Copyright © 2019 Susan A. S. Farhadi and Kawa F. Dizaye. 2019
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

通讯作者

Susan A. S. Farhadi.Department of Basic Sciences/ Pharmacology Unit, College of Medicine, Hawler Medical University, Erbil, Iraq, hmu.edu.iq.susan.abdulkadir@hmu.edu.krd

推荐引用方式

Susan A. S. Farhadi,Kawa F. Dizaye. Aliskiren, Fosinopril, and Their Outcome on Renin-Angiotensin-Aldosterone System (RAAS) in Rats with Thyroid Dysfunction. International Journal of Endocrinology ,Vol.2019(2019)

您觉得这篇文章对您有帮助吗?
分享和收藏
0

是否收藏?

参考文献
[1] G. De Sarro, E. D. Paola, S. Gratteri, P. Gareri. et al.(2012). Fosinopril and zofenopril, two angiotensin-converting enzyme (ACE) inhibitors, potentiate the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in DBA/2 mice. Pharmacological Research.65(3):285-296. DOI: 10.1016/j.ecl.2014.02.005.
[2] J. Chen, Y. Shiau, Y. Tseng, H. Chiu. et al.(2010). Concurrent sympathetic activation and vagal withdrawal in hyperthyroidism: evidence from detrended fluctuation analysis of heart rate variability. Physica A: Statistical Mechanics and its Applications.389(9):1861-1868. DOI: 10.1016/j.ecl.2014.02.005.
[3] V. Triggiani, M. Iacoviello. (2013). Thyroid disorders in chronic heart failure: From prognostic set-up to therapeutic management. Endocrine, Metabolic & Immune Disorders—Drug Targets.13(1):22-37. DOI: 10.1016/j.ecl.2014.02.005.
[4] U. Subudhi, G. B. Chainy. (2010). Expression of hepatic antioxidant genes in l-thyroxine-induced hyperthyroid rats: regulation by vitamin E and curcumin. Chemico-Biological Interactions.183(2):304-316. DOI: 10.1016/j.ecl.2014.02.005.
[5] S. A. Atlas. (2007). The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. Journal of Managed Care Pharmacy.13(8, Suppl B):9-20. DOI: 10.1016/j.ecl.2014.02.005.
[6] K. F. Dizaye, C. Y. Qadir. (2014). Effects of benfotiamine and methylcobalamin on paclitaxel induced peripheral neuropathy. Middle East Journal of Internal Medicine.63(1139):1-1. DOI: 10.1016/j.ecl.2014.02.005.
[7] C. Vlachopoulos, D. Terentes-Printzios. (2015). Thyroid, aldosterone, and cardiovascular disease. Heart and Metabolism(66):3-6. DOI: 10.1016/j.ecl.2014.02.005.
[8] J. L. Pool. (2007). Direct renin inhibition: focus on aliskiren. Journal of Managed Care Pharmacy.13(8, Suppl B):21-33. DOI: 10.1016/j.ecl.2014.02.005.
[9] N. Muñoz-Durango, C. A. Fuentes, A. E. Castillo, L. M. González-Gómez. et al.(2016). Role of the renin-angiotensin-aldosterone system beyond blood pressure regulation: molecular and cellular mechanisms involved in end-organ damage during arterial hypertension. International Journal of Molecular Sciences.17(7):797. DOI: 10.1016/j.ecl.2014.02.005.
[10] W. Wang, Z. Y. Lu, Z. Ren, G. Z. Zhang. et al.(2016). Effect of alprostadil combined with fosinopril therapy on renal function and oxidative stress in patients with diabetic nephropathy. Journal of Hainan Medical University.22(16):40-43. DOI: 10.1016/j.ecl.2014.02.005.
[11] A. P. MüLler, A. Longoni, M. Farina, C. K. Da Silveira. et al.(2013). Propylthiouracil-induced hypothyroidism during lactation alters leucine and mannose metabolism in rat cerebellar slices. Experimental Biology and Medicine.238(1):31-36. DOI: 10.1016/j.ecl.2014.02.005.
[12] M. Fagyas, K. Úri, I. M. Siket, A. Daragó. et al.(2014). New perspectives in the renin-angiotensin-aldosterone system (RAAS) I: endogenous angiotensin converting enzyme (ACE) inhibition. Plos One.9(4). DOI: 10.1016/j.ecl.2014.02.005.
[13] M. Mohamedali, S. R. Maddika, A. Vyas. (2014). Thyroid disorders and chronic kidney disease. International Journal of Nephrology.2014-6. DOI: 10.1016/j.ecl.2014.02.005.
[14] S. Danzi, I. Klein. (2014). Thyroid disease and the cardiovascular system. Endocrinology and Metabolism Clinics of North America.43(2):517-528. DOI: 10.1016/j.ecl.2014.02.005.
[15] P. Uutela, M. Monto, I. Iso-Mustajärvi, M. Madetoja. et al.(2014). Identification of metabolites of fosinopril produced by human and rat liver microsomes with liquid chromatography–mass spectrometry. European Journal of Pharmaceutical Sciences.53:86-94. DOI: 10.1016/j.ecl.2014.02.005.
[16] A. Kumar N, M. Shanthi, R. Parameswari. (2013). The effect of L-thyroxine on metabolic parameters in newly diagnosed primary hypothyroidism. Clinical & Experimental Pharmacology.3(3):1-4. DOI: 10.1016/j.ecl.2014.02.005.
[17] V. Kaur, K. Singh, M. Verma. (2015). Changes in biochemical markers of renal function in subclinical and overt hypothyroidism. International Journal of Bioassays.4(4):3799-3802. DOI: 10.1016/j.ecl.2014.02.005.
[18] W. J. Frenkel. (2014). Susceptibility to Hyponatremia in the Elderly: Causes and Consequences. DOI: 10.1016/j.ecl.2014.02.005.
[19] L. Sbârcea, I. Ledeţi, L. Drăgan, L. Kurunczi. et al.(2015). Fosinopril sodium–hydroxypropyl--cyclodextrin inclusion complex. Journal of Thermal Analysis and Calorimetry.120(1):981-990. DOI: 10.1016/j.ecl.2014.02.005.
[20] K. F. Dizaye, A. A. Ahmed. (2016). Renoprotective evaluations of different angiotensin inhibitors on diabetic nephropathy in rats. Middle East Journal of Internal Medicine.63(4023):1-9. DOI: 10.1016/j.ecl.2014.02.005.
[21] W. W. Batenburg, R. J. de Bruin, J. M. van Gool, D. N. Müller. et al.(2008). Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arteriosclerosis, Thrombosis, and Vascular Biology.28(6):1151-1157. DOI: 10.1016/j.ecl.2014.02.005.
[22] M. S. Carneiro-Ramos, V. B. Silva, R. A. Santos, M. L. Barreto-Chaves. et al.(2006). Tissue-specific modulation of angiotensin-converting enzyme (ACE) in hyperthyroidism. Peptides.27(11):2942-2949. DOI: 10.1016/j.ecl.2014.02.005.
[23] F. T. Hammad, S. Al-Salam, L. Lubbad. (2013). Does aliskiren protect the kidney following ischemia reperfusion injury?. Physiological Research.62(6):681-690. DOI: 10.1016/j.ecl.2014.02.005.
[24] J. K. Sangster, D. L. Panciera, J. A. Abbott. (2013). Cardiovascular effects of thyroid disease. Compendium on Continuing Education for the Practising Veterinarian.35(7):E5. DOI: 10.1016/j.ecl.2014.02.005.
[25] J. R. Tata. (2011). Looking for the mechanism of action of thyroid hormone. Journal of Thyroid Research.2011-12. DOI: 10.1016/j.ecl.2014.02.005.
[26] F. Vargas, I. Rodríguez-Gómez, P. Vargas-Tendero, E. Jimenez. et al.(2012). The renin-angiotensin system in thyroid disorders and its role in cardiovascular and renal manifestations. Journal of Endocrinology.213(1):25-36. DOI: 10.1016/j.ecl.2014.02.005.
[27] A. L. Coughtrie, C. Doe, D. Layton, S. A. W. Shakir. et al.(2016). Utilisation and tolerability of aliskiren in the primary care setting in England. The Journal of Clinical Hypertension.18(12):1237-1243. DOI: 10.1016/j.ecl.2014.02.005.
[28] S. Vaidyanathan, M. Maboudian, V. Warren, C. Yeh. et al.(2008). A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects. Current Medical Research and Opinion.24(8):2313-2326. DOI: 10.1016/j.ecl.2014.02.005.
[29] R. G. Ahmed. (2018). Hyperthyroidism and renal disorders. ARC Journal of Animal and Veterinary Sciences.4(2):1-5. DOI: 10.1016/j.ecl.2014.02.005.
[30] P. Dousdampanis, K. Trigka, G. A. Vagenakis, C. Fourtounas. et al.(2014). The thyroid and the kidney: a complex interplay in health and disease. The International Journal of Artificial Organs.37(1):1-2. DOI: 10.1016/j.ecl.2014.02.005.
[31] P. Iglesias, M. A. Bajo, R. Selgas, J. J. Díez. et al.(2017). Thyroid dysfunction and kidney disease: an update. Reviews in Endocrine and Metabolic Disorders.18(1):131-144. DOI: 10.1016/j.ecl.2014.02.005.
[32] Z. Gluvic, E. Sudar, J. Tica. (2015). Effects of levothyroxine replacement therapy on parameters of metabolic syndrome and atherosclerosis in hypothyroid patients: a prospective pilot study. International Journal of Endocrinology.2015-9. DOI: 10.1016/j.ecl.2014.02.005.
[33] H. P. Rang, J. M. Ritter, R. J. Flower, G. Henderson. et al.(2014). Rang & Dale's Pharmacology. DOI: 10.1016/j.ecl.2014.02.005.
[34] R. Mullur, Y.-Y. Liu, G. A. Brent. (2014). Thyroid hormone regulation of metabolism. Physiological Reviews.94(2):355-382. DOI: 10.1016/j.ecl.2014.02.005.
[35] W. Drummond, M. A. Munger, M. Rafique Essop, M. Maboudian. et al.(2007). Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. Journal of Clinical Hypertension (Greenwich, Conn.).9(10):742-750. DOI: 10.1016/j.ecl.2014.02.005.
[36] L. M. Prisant, J. S. Gujral, A. L. Mulloy. (2006). Hyperthyroidism: a secondary cause of isolated systolic hypertension. Journal of Clinical Hypertension (Greenwich, Conn.).8(8):596-599. DOI: 10.1016/j.ecl.2014.02.005.
[37] J. Nussberger, G. Wuerzner, C. Jensen, H. R. Brunner. et al.(2002). Angiotensin II Suppression in humans by the orally active renin inhibitor aliskiren (SPP100) comparison with enalapril. Hypertension.39(1):e1-e8. DOI: 10.1016/j.ecl.2014.02.005.
文献评价指标
浏览 5次
下载全文 0次
评分次数 0次
用户评分 0.0分
分享 0次